glp-1/gip Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Beyond the pancreas: contrasting cardiometabolic
Description
Our findings strongly suggest the answer is yes. Primes recent real-world study found 63% of high-potency GLP-1 (Wegovy or Zepbound) users who started treatment in Q1 2024 are still taking their medication after a year
Learn more about its role in diabetes management.
Starting semaglutide or tirzepatide
Adults with obesity and autoimmune disease taking GLP-1 medication experience fewer cardiac events and have a lower risk of death, according to new findings.
prices closer to global standards.
Plus, it primes your body to stay in fat-burning mode, bringing you one step closer to a leaner, sculpted physique
